Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced that the latest research progress of JSKN003 was announced during the 2026 ESMO conference poster presentation. The JSKN003 combination treatment showed outstanding anti-tumor activity in HER2+ GC/GEJ first-line treatment. Among them, Cohort B showed outstanding performance: achieved 100% ORR, all patients achieved PR, and at the same time had better safety characteristics. This is the first clinical evidence that ADC combined with its parent antibody to enhance efficacy. This data supports continued patient enrollment and longer follow-up cycles in this study.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced that the latest research progress of JSKN003 was announced during the 2026 ESMO conference poster presentation. The JSKN003 combination treatment showed outstanding anti-tumor activity in HER2+ GC/GEJ first-line treatment. Among them, Cohort B showed outstanding performance: achieved 100% ORR, all patients achieved PR, and at the same time had better safety characteristics. This is the first clinical evidence that ADC combined with its parent antibody to enhance efficacy. This data supports continued patient enrollment and longer follow-up cycles in this study.